Core Viewpoint - Meili Tianyuan Medical Health (02373) demonstrates strong confidence in its future development through share buybacks and insider purchases, indicating a belief that current share prices do not reflect the company's intrinsic value [1] Group 1: Insider Transactions - Non-executive director Yi Lin purchased a total of 61,000 shares in the open market on October 24, 2025, using personal funds, reflecting a strong belief in the company's future prospects [1] Group 2: Share Buyback Activity - On October 30, 2025, the company repurchased 30,000 shares at a total cost of approximately 927,150 HKD, with an average price of about 30.91 HKD per share [1] - From October 15, 2025, to the date of the announcement, the company has repurchased a total of 475,000 shares for a total consideration of approximately 15,069,220 HKD [1] Group 3: Management's Perspective - The board believes that the current trading price does not reflect the intrinsic value of the shares and the actual business prospects of the company [1] - The board asserts that the share buyback reflects management's strong confidence in the long-term value of the enterprise and is beneficial for enhancing the company's market value and shareholder return capabilities [1]
美丽田园医疗健康(02373)获非执行董事易琳增持6.1万股